Cytek Biosciences (CTKB) EBITDA (2020 - 2026)

Cytek Biosciences (CTKB) has reported EBITDA for 7 consecutive years, with -$11.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBITDA fell 7.3% year-over-year to -$11.4 million; the trailing twelve-month figure through Jun 2026 stood at -$44.6 million (down 66.22% YoY), and the FY2025 full-year result was -$40.4 million, down 96.77% from the prior year.
• EBITDA improved to -$11.4 million in Q2 2026 per CTKB's latest filing, from -$18.5 million in the prior quarter.
• Across five years, EBITDA topped out at $3.0 million in Q4 2024 and bottomed at -$18.5 million in Q1 2026.
• Historically, EBITDA has averaged -$6.7 million across 5 years, with a median of -$7.5 million in 2023.
• The sharpest annual moves came in 2023 and 2024: EBITDA slumped 924.35% in 2023, then soared 2279.56% in 2024.
• Over 5 years, EBITDA stood at $84000.0 in 2022, then sank by 263.1% to -$137000.0 in 2023, then jumped by 2279.56% to $3.0 million in 2024, then plunged by 287.34% to -$5.6 million in 2025, then tumbled by 103.79% to -$11.4 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$11.4 million, -$18.5 million, and -$5.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.